Keyword: Puma Biotechnologies
Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.
Puma said it's working on improving patient discontinuations caused by side effects, but analysts want to see more.
Whatever M&A hope Puma investors previously had for a buyout may have just been shattered by a European Nerlynx licensing deal.
A North Carolina federal jury found that Puma maliciously defamed Eshelman amid a proxy fight that began in late 2015.
Puma's former senior director of regulatory affairs made more than $1 million by trading on nonpublic information, authorities say.
Two weeks after winning approval and one month ahead of its previous launch timeline, Puma Biotechnology introduced new cancer medication Nerlynx.
Puma reportedly set a price of $126,000 per year for its brand-new breast cancer drug Nerlynx—and analysts are hiking sales forecasts because of it.
Analysts expect Nerlynx to gin up blockbuster sales by 2022, thanks to a 'best case' approval from the FDA.
As California’s Puma Biotechnology awaits FDA word on its breast cancer drug neratinib, an Advera Health analysis outlines the drug's risks and paints a mixed picture for efficacy versus Roche’s Herceptin and Novartis’ Tykerb.